U.S. FDA approves migraine drug from Glaxo, Pozen

NEW YORK, April 15 (Reuters) - The U.S. Food and Drug Administration has approved a combination migraine drug from GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research, Stock Buzz) (GSK.N: Quote, Profile, Research, Stock Buzz) and Pozen Inc (POZN.O: Quote, Profile, Research, Stock Buzz), the companies said on Tuesday.

The drug, Treximet, is expected to be available in U.S. pharmacies by the middle of May, the companies said.

FDA officials had earlier expressed concern over heart safety and the risk of gene toxicity, asking for more data. (Reporting by Justin Grant, with additional reporting by Susan Heavey in Washington; Editing by Braden Reddall)